{
    "nctId": "NCT01672671",
    "briefTitle": "BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy",
    "officialTitle": "Identification of BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy",
    "overallStatus": "COMPLETED",
    "conditions": "Early Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 41,
    "primaryOutcomeMeasure": "The pathological complete response rate to neoadjuvant platinum-based chemotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients, age \u226518 years\u226475;\n2. Histologically confirmed invasive ER-, PR-, and HER2-negative (triple- negative) adenocarcinoma of the breast;\n3. Clinical stage T1-2, N0-1, M0.\n\nExclusion Criteria:\n\n1. Previous treatment for this breast cancer\n2. History of malignancy treated with curative intent within the previous 5 years with the exception of skin cancer, cervical carcinoma in situ, or follicular thyroid cancer. Patients with previous invasive cancers (including breast cancer) are eligible if the treatment was completed more than 5 years prior to initiating current study treatment, and there is no evidence of recurrent disease\n3. Pregnancy or breast-feeding",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}